Clinical trials: COVID, Coronavirus
COVID-19
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
This is an open label, randomized, controlled, pilot clinical study in patients with COVID-19, to obtain preliminary biologic, physiologic, and clinical data in patients with COVID-19 treated with rhACE2 or control patients, to…
- Trial name
- NCT04287686
- Testing
- Recombinant human angiotensin-converting enzyme 2 (rhACE2)
- Where
- China
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
COVID-19
Mechanisms Underlying Cardiovascular Consequences Associated With COVID-19 and Long COVID
AIM 1. Characterize cardiovascular phenotypes of long COVID by cardiopulmonary, meta-bolic, and cardiac mechanical/physiological responses to exercise and microvascular vasomotor function. AIM 2.
- Trial name
- NCT06427512
- Where
- United States
- Sponsor
- Columbia University
COVID-19 Infection
Immunosupressive Treatment in COVID-19 Patients
SAM-COVID is a retrospective cohort study that aims to determine the impact of immunosuppressive drugs and immunoglubulins in the outcome of patients with COVID-19.
- Trial name
- SAM-COVID (NCT04382781)
- Testing
- NO-Immunosuppressive, Immunosuppressive, Immunoglubulins
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Spanish Network for Research in Infectious Diseases
Covid19, COVID-19 Pneumonia
Efficacy and Safety of Antimicrobial Stewardship Intervention in Hospitalized COVID-19 Patients (COVASP)
COVID-19 is respiratory disease caused by the severe acute respiratory coronavirus 2 (SARS-CoV-2), a novel coronavirus which has spread rapidly across the world with over 149.9 million laboratory confirmed cases and over 3.1…
- Conditions
- Covid19, COVID-19 Pneumonia, COVID-19 Lower Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- COVASP (NCT04896866)
- Testing
- Antimicrobial stewardship prospective audit and feedback
- Where
- 3 sites in Canada
- Volunteers
- 833 people
- Sponsor
- University of Alberta
Covid19
Aggrenox To Treat Acute Covid-19
The purpose of this study is to explore the efficacy of Aggrenox in patients with SARS-CoV-2 infection with symptoms consistent with COVID-19.
- Trial name
- ATTAC-19 (NCT04410328)
- Testing
- Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care, Standard of care
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Rutgers, The State University of New Jersey
COVID19, Hematologic Malignancy
Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)
The primary objective of this phase 2, multicentric, placebo-controlled double-blind, randomized study is to evaluate the efficacy of the combination of hydroxychloroquine and azithromycine on the viral load drop at day 5 among…
- Trial name
- HYACINTHE (NCT04392128)
- Testing
- Hydroxychloroquine Sulfate 200 MG [Plaquenil], Azithromycin 250 MG Oral Capsule
- Where
- France
- Sponsor
- Institut de cancérologie Strasbourg Europe
COVID-19
Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above
This is a randomized, blinded, positive-controlled study to evaluate the immunogenicity and safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, in population aged 18 years old and above（negative antibody against…
- Trial name
- NCT05663086
- Testing
- One dose group, Two doses group, Aged 18-59 years
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
SARS-CoV-2, COVID-19
Epidemiology, Immunology and Clinical Characteristics of COVID-19 (EPIC3)
The purpose of this research is to gather information to answer questions about the Coronavirus Disease 2019 (COVID-19) which is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.
- Trial name
- EPIC3 (NCT05764083)
- Where
- United States
- Volunteers
- 2,824 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
COVID 19
Convalescent Plasma for COVID-19 Patients
The investigators propose to evaluate intravenous administration of convalescent plasma (CP) obtained from COVID19 survivors in COVID19 patients who are in the medium stage.
- Trial name
- CPCP (NCT04516954)
- Testing
- Convalescent COVID 19 Plasma
- Where
- Vietnam
- Volunteers
- 4 people
- Sponsor
- Vinmec Research Institute of Stem Cell and Gene Technology
COVID-19
Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19
Randomized open-label multicenter parallel-group study of efficacy and safety of TL-FVP-t vs. standard of care therapy in patients with mild to moderate coronavirus disease (SARS-CoV-2/COVID-19)
- Trial name
- NCT04501783
- Testing
- Favipiravir, Standard of care (SOC), standard concomitant therapy
- Where
- 10 sites in Russia
- Volunteers
- 168 people
- Sponsor
- R-Pharm
Post-COVID-19 Syndrome, Long-COVID-19 Syndrome
Fat Oxidation Capacity in Patients With Post Covid-19 Syndrome
Post-COVID-19 Syndrome (PCS) is characterized by symptoms, including fatigue, reduced physical performance, dyspnea, cognitive impairment, and psychological distress.
- Trial name
- NCT06468722
- Testing
- Exercise-based rehabilitation
- Where
- Germany
- Volunteers
- 187 people
- Sponsor
- University of Witten/Herdecke
COVID-19
A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People
The purpose of this study is to characterize descriptively the BNT162b2 vaccination safety experience among the Indonesian people.
- Trial name
- NCT05621239
- Testing
- BNT162b2
- Where
- Indonesia
- Volunteers
- 260 people
- Sponsor
- Pfizer
Covid19
A Wearable, Battery-free Screening System for SARS-CoV-2, the Virus Causing COVID-19 Infection
The corona virus disease (COVID) pandemic has highlighted the importance of rapid, readily available screeners and diagnostics to identify infected individuals.
- Trial name
- NCT04807075
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Nebraska
COVID-19
Respiratory Physiotherapy in Severe COVID-19 Patients
COVID-19 is an infectious disease caused by SARS-CoV2 virus. COVID-19 patients can develop a severe disease that can lead to hypoxic respiratory failure and acute respiratory distress syndrome (ARDS).
- Trial name
- FTR-COVID (NCT04459819)
- Testing
- Respiratory physiotherapy
- Where
- Italy
- Volunteers
- 84 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
COVID-19
A Study of S-892216 in Participants With COVID-19
The primary objective of this study is to investigate the antiviral effect of S-892216 in participants with coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
- Trial name
- NCT06928051
- Testing
- S-892216
- Where
- 57 sites in United States, Japan
- Volunteers
- 282 people
- Sponsor
- Shionogi
Covid19
Covid-19 Long-term Revalidation Follow-up
In this monocentric, prospective and descriptive trial we want to evaluate the long-term consequences for patients treated for Covid-19. Covid patients who were hospitalized for min.
- Trial name
- Colonel (NCT04685629)
- Testing
- 25 post ICU-patients, 25 post non-ICU patients
- Where
- Belgium
- Sponsor
- University Hospital, Antwerp
COVID, Sars-CoV2
Using GM-CSF as a Host Directed Therapeutic Against COVID-19
The coronavirus disease 2019 (COVID-19) has rapidly become a pandemic. COVID-19 poses a mortality risk of 3-7%, rising to 20% in older patients with co-morbidities.
- Conditions
- COVID, Sars-CoV2, ARDS, Human
- Trial name
- NCT04400929
- Testing
- Sargramostim, Normal Saline 0.9%
- Where
- Singapore
- Volunteers
- 2 people
- Sponsor
- Singapore General Hospital
COVID-19, Coronavirus Infections
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant
VBI-2901e is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and…
- Trial name
- NCT05614245
- Testing
- VBI-2901e
- Where
- 4 sites in Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Antigen Rapid Diagnostic Tests for Community Identification of Severe Acute Respiratory Syndrome Coronavirus 2
Background: Background: Testing with antigen-detecting rapid diagnostic tests (Ag-RDTs), including in asymptomatic individuals, has the potential to promptly identify more Severe Acute Respiratory Syndrome Coronavirus 2…
- Trial name
- NCT05458557
- Testing
- Rapid Antigen Testing
- Where
- Kenya
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Elizabeth Glaser Pediatric AIDS Foundation
SARS-CoV2 Infection
Use of Saliva for COVID-19 Diagnosis
Aim of the study is to evaluate the presence of SARS-CoV2 RNA in the saliva of patients with suspected or confirmed COVID-19 in order to validate the analysis of this type of sample for the diagnosis of SARS-CoV2 infections.
- Trial name
- SALIVA-01 (NCT04953039)
- Where
- Italy
- Volunteers
- 109 people
- Sponsor
- University of Milano Bicocca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.